Printer Friendly

SPI PHARMACEUTICALS INTRODUCES THIRD GENERATION ANTIBIOTIC IN MEXICO

 COSTA MESA, Calif., Dec. 3 /PRNewswire/ -- SPI Pharmaceuticals, Inc. (AMEX: SPI) announced today the introduction in Mexico of ciprofloxacin, a broad-spectrum third-generation antibiotic. The prescription pharmaceutical will be marketed as Eni(R) capsules.
 Eni is used to treat a wide variety of bacterial infections. It is authorized in Mexico for respiratory infections, involving pneumonia and cystic fibrosis; ear nose and throat infections; skin and soft tissue infections including ulcers and infected burns; gastrointestinal infections; eye infections; and infections resulting from surgical wounds.
 Introduction of ciprofloxacin in Mexico follow SPI's recent launch in Mexico of Oseum(R) (salmon calcitonin) for the treatment of osteoporosis.
 "The launch of Eni signals SPI's continuing growth in Mexico," said Adam Jerney, president and chief operating officer of SPI. "Coming on the heels of a successful launch of Oseum, the introduction of Eni is an excellent example of our international capabilities to geographically expand product lines throughout our international manufacturing, marketing and distribution system."
 Mexican operations account for 16 percent of SPI's total revenues. One of the largest pharmaceutical firms in Mexico, SPI has established a major presence in the oral and injectable and anti-infective market. The company's antiviral Virazole is now the largest selling oral and injectable antiviral in the country. In addition, the company makes and markets a broad line of antibiotics. SPI has 814 employees in Mexico.
 SPI Pharmaceuticals, Inc., headquartered in Costa Mesa, Calif., manufactures, markets and distributes more than 600 prescription and non-prescription pharmaceuticals in over 60 countries, including North America, Western and Eastern Europe, and the Far East. It is an operating unit of ICN Pharmaceuticals, Inc. (NYSE: ICN).
 -0- 12/3/93
 /CONTACT: Jack Sholl of SPI Pharmaceuticals, Inc., 714-545-0100, ext. 3013/
 (SPI ICN)


CO: SPI Pharmaceuticals, Inc.; ICN Pharmaceuticals, Inc. ST: California IN: MTC SU: PDT

LD-PS -- NY002 -- 0095 12/03/93 08:02 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1993
Words:307
Previous Article:CIMCO ANNOUNCES SECOND QUARTER RESULTS FOR FISCAL YEAR 1994
Next Article:PANAMSAT SET TO LAUNCH GLOBAL SYSTEMWITH CLOSE TO US $1 BILLION IN PRE-LAUNCH AGREEMENTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters